Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 281, 160-167
Abstract
No abstract availableKeywords
Funding Information
- Dainippon Sumitomo Pharma
This publication has 25 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Antidepressants for the Acute Treatment of Bipolar DepressionThe Journal of Clinical Psychiatry, 2010
- Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2010
- A systematic review of the evidence of the burden of bipolar disorder in EuropeClinical Practice & Epidemiology in Mental Health, 2009
- Impact of Depressive Symptoms Compared With Manic Symptoms in Bipolar DisorderThe Journal of Clinical Psychiatry, 2004
- A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorderCurrent Medical Research and Opinion, 2004
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959